NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Dronedarone for atrial fibrillation

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
 Manufacturers/sponsors Sanofi Aventis (dronedarone) Patient/carer groups AntiCoagulation Europe (ACE) Arrhythmia Alliance (AFA Affiliated) Atrial Fibrillation Association (AFA) Stroke Association Grown Up Congenital Heart Patients Association 	 General Department of Health, Social Services and Public Safety for Northern Ireland Medicines and Healthcare products Regulatory Agency NHS Quality Improvement Scotland Comparator manufacturers None Relevant research groups
 Professional groups British Association of Stroke Physicians British Cardiovascular Intervention 	Heart Failure Research Group, University of Glasgow Evidence Review Group
Society (BCIS) British Heart Foundation Heart Rhythm UK Primary Care Cardiovascular Society Royal College of Nursing Royal College of Physicians	 NHS Centre for Reviews & Dissemination and Centre for Health Economics, York National Institute for Health Research Health Technology Assessment Programme
 Cardiology Committee Society of Cardiothoracic Surgeons of Great Britain and Ireland 	Associated Guideline GroupsNational Collaborating Centre for Chronic Conditions
OthersDepartment of HealthHounslow PCTWelsh Assembly Government	Associated Public Health Groups None

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which

National Institute for Health and Clinical Excellence

Matrix for the appraisal of dronedarone for atrial fibrillation and atrial flutter

Issue date: June 2009

organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*.

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

National Institute for Health and Clinical Excellence

Matrix for the appraisal of dronedarone for atrial fibrillation and atrial flutter

Issue date: June 2009